Pulmonary aspergillosis in a Crohn's disease patient receiving adalimumab and steroid therapy
Gastroenterol Hepatol. 2019 Jun-Jul;42(6):387-388.
doi: 10.1016/j.gastrohep.2018.05.028.
Epub 2018 Jul 2.
[Article in
English,
Spanish]
Affiliations
- 1 Unidad de Enfermedad Inflamatoria Intestinal, Departamento de Gastroenterología, Hospital de Manises, Manises, Valencia, España. Electronic address: ifebrad@gmail.com.
- 2 Unidad de Enfermedad Inflamatoria Intestinal, Departamento de Gastroenterología, Hospital de Manises, Manises, Valencia, España.
No abstract available
MeSH terms
-
Adalimumab / adverse effects*
-
Adalimumab / therapeutic use
-
Adrenal Cortex Hormones / adverse effects*
-
Adrenal Cortex Hormones / therapeutic use
-
Adult
-
Anti-Inflammatory Agents / adverse effects*
-
Anti-Inflammatory Agents / therapeutic use
-
Antifungal Agents / therapeutic use
-
Cilastatin / therapeutic use
-
Crohn Disease / complications
-
Crohn Disease / drug therapy*
-
Diagnosis, Differential
-
Disease Susceptibility
-
Humans
-
Imipenem / therapeutic use
-
Immunocompromised Host
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / therapeutic use
-
Male
-
Opportunistic Infections / diagnosis
-
Opportunistic Infections / drug therapy
-
Opportunistic Infections / etiology*
-
Pulmonary Aspergillosis / diagnosis
-
Pulmonary Aspergillosis / drug therapy
-
Pulmonary Aspergillosis / etiology*
-
Tomography, X-Ray Computed
-
Tuberculosis, Pulmonary / diagnosis
Substances
-
Adrenal Cortex Hormones
-
Anti-Inflammatory Agents
-
Antifungal Agents
-
Immunosuppressive Agents
-
Cilastatin
-
Imipenem
-
Adalimumab